Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. develops allosteric small molecule therapies for neurodegenerative and other difficult-to-treat diseases. The company’s lead candidate, GT-02287, is being developed for Parkinson’s disease with or without a GBA1 mutation and is designed as a brain-penetrant allosteric enzyme modulator of glucocerebrosidase, or GCase.
Recurring news for GANX includes financial results, corporate updates, clinical and biomarker data for GT-02287, FDA and IND-related communications, and scientific presentations at Parkinson’s and neurodegeneration conferences. Company updates also cover the Magellan™ drug discovery platform, preclinical GCase modulator programs such as GT-04686, and pipeline areas including lysosomal storage disorders, metabolic diseases and solid tumors.
Gain Therapeutics, Inc. (Nasdaq: GANX) has successfully completed its IPO, raising approximately $46 million in gross proceeds. The company has appointed four independent board members to enhance leadership and signed a collaboration agreement with Zentalis Pharmaceuticals to develop cancer treatments. Positive pre-clinical data was presented at the WorldSymposium™. For Q1 2021, the company reported net loss of $2.45 million with cash reserves of $46.59 million.
Gain Therapeutics, Inc. (NASDAQ: GANX) announced promising pre-clinical data from its GBA1 Parkinson's disease program at the IAPRD World Congress. The data highlights the potential of their Structurally Targeted Allosteric Regulators (STARs), which stabilize and restore activity of mutated GCase, leading to decreased levels of phosphorylated and aggregated α-synuclein. Key candidates GT-02287 and GT-02329 were effective in reversing neurodegeneration in animal models, suggesting a new therapeutic avenue for GBA1-related Parkinson's disease. The research was recognized as one of the top 10 abstracts presented at the conference.
Gain Therapeutics, Inc. (NASDAQ: GANX) announced its CEO, Eric Richman, will present at the B. Riley Securities’ Virtual Neuroscience Conference on April 28-29 at 4:00 p.m. ET. The company focuses on innovative drug discovery using its SEE-Tx™ platform to identify allosteric binding sites for challenging disorders linked to protein misfolding. Since its establishment in 2017, Gain has secured funding from notable organizations, including The Michael J. Fox Foundation and Eurostars-2 program. For more details, visit Gain Therapeutics.
Gain Therapeutics, Inc. (NASDAQ: GANX) announced its STAR candidate for Parkinson's disease has been selected among the 10 Best Abstracts at the IAPRD 2021 World Congress. The poster presentation, led by Roberto Maj, Pharm.D., showcases the potential of the company's structurally targeted allosteric regulators (STARs) to improve motor deficits in an in vivo model of Parkinson's disease. The conference will be held virtually from May 1-4, 2021, and the presentation will remain accessible throughout the event.
Gain Therapeutics, Inc. (NASDAQ: GANX) announced a multi-target collaboration with Zentalis Pharmaceuticals (NASDAQ: ZNTL) to identify new oncology drug targets using its proprietary SEE-Tx computational platform. This technology employs supercomputers to analyze protein structures for novel binding sites, enhancing drug discovery. Gain's CEO highlighted Zentalis' expertise in cancer treatments as a key asset for validating the SEE-Tx platform. This partnership aims to address challenges in cancer treatment through innovative target identification.
Gain Therapeutics, Inc. has successfully closed its initial public offering (IPO) of 3,636,364 shares of common stock, including the full exercise of the underwriters’ overallotment option for an additional 545,454 shares at a public offering price of $11.00 each. The gross proceeds from this offering amount to approximately $46 million, prior to deductions for underwriting discounts and expenses. Gain's shares are traded on the Nasdaq Global Market under the symbol GANX. The registration statement for this offering was made effective by the SEC on March 17, 2021.
Gain Therapeutics, Inc. has priced its initial public offering (IPO) at $11.00 per share, offering 3,636,364 shares under the symbol 'GANX'. Trading is set to commence on March 18, 2021, with the offering expected to close on March 22, 2021, subject to customary conditions. Underwriters hold a 30-day option to purchase an additional 545,454 shares. The SEC declared the registration statement effective on March 17, 2021. Gain Therapeutics aims to transform drug discovery with its See-Tx™ platform, targeting challenging disorders linked to protein misfolding.